Low Dose Dexmedetomidine and Delirium After Cardiac Surgery (LOWDEXDEL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03388541|
Recruitment Status : Recruiting
First Posted : January 3, 2018
Last Update Posted : November 29, 2018
Delirium after cardiac surgery can occur in up to 50% of the patients and has been shown to be significantly associated with increased morbidity and mortality. Advanced age is a significant risk factor of delirium.
Numerous studies have shown that sedation with high doses of Dexmedetomidine in the ICU reduces the incidence of postoperative delirium. On the other hand animal studies have shown neuroprotective effects of Dexmedetomidine by means of stimulating alpha2A-adrenoceptors.
It is not clear whether the administration of a low dose Dexmedetomidine in cardiac surgery would have any neuroprotective effects by stimulating the alpha 2A-receptors and as such would decrease the incidence of postoperative delirium.
|Condition or disease||Intervention/treatment||Phase|
|Cardiac Surgical Procedures||Drug: Dexmedetomidine Drug: Placebo||Phase 4|
Postoperative delirium (PD) is a common problem in cardiac surgical patients. Its incidence varies among studies and can reach up to 50% of the patients. PD is associated with increased morbidity and mortality. Its occurrence is the resultant between the predisposing factors and the precipitating factors. Age seems to be a significant predisposing factor. In this regard the pathophysiology of PD is not yet fully understood. There are several hypothetical mechanisms for the development of PD. The first hypothesis is cerebral ischemia and BBB breakdown. The second hypothesis is neuro-inflammation. Peripheral pro-inflammatory mediators especially released during surgery would interact with the brain. Otherwise there is the problem of sleep deprivation/fragmentation in patients admitted to the hospital.
Dexmedetomidine is a potent and more selective alpha2-adrenergic receptor than clonidine. Studies have demonstrated that it has neuroprotective and anti-inflammatory actions.
Numerous studies including trials in cardiac surgery have shown a decreased incidence of delirium when Dexmedetomidine was used as sedative in the ICU compared with other sedatives acting on the GABA receptors. However, in these studies high doses of Dexmedetomidine were used for periods up to 24h. Dexmedetomidine was started in the ICU and was not compared in a double-blind fashion with placebo. In a recent randomized double-blind placebo-controlled trial a very low dose of Dexmedetomidine decreased the occurrence of PD when compared to placebo. However this study was performed in non-cardiac patients. Moreover the patients were included after their arrival in the ICU, which means that those patients who were intubated at their arrival in the ICU were not included. And again the study medication was only started after arrival in the ICU.
The aim of this study is to elucidate whether the administration of Dexmedetomidine at a low dose would decrease the incidence of PD in elderly patients undergoing cardiac surgery. The hypothesis is that Dexmedetomidine at low doses, by only stimulating the alpha2A adrenoceptors,would have neuroprotective affects ans as such decrease the incidence of PD. Dexmedetomidine would also have anti-inflammatory effects and effects on the quality of sleep. Both mechanisms would play a role in the pathophysiology of PD.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||420 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Does LOW Dose DEXmedetomidine After Cardiopulmonary Bypass Separation Decrease the Incidence of DELirium: A Double-blind Randomized Placebo-controlled Study (LOWDEXDEL Study)|
|Actual Study Start Date :||January 17, 2018|
|Estimated Primary Completion Date :||January 30, 2020|
|Estimated Study Completion Date :||January 30, 2020|
Active Comparator: Dexmedetomidine
Dexmedetomidine will be administered at 0.4ug/kg/h (5mL/h) starting at the closure of the chest and continued during 10h.
Dexmedetomidine will be started at 5mL/h while the patient is still in the operating room.
Placebo Comparator: Placebo
NaCl 0.9% will be administered at 5mL/h starting at the closure of the chest and continued during 10h.
- The incidence of delirium [ Time Frame: Through study completion, an average of 30 days ]The incidence of delirium detected by means of CAM-ICU and CAM
- Number of days spent in delirium [ Time Frame: Through study completion, an average of 30 days ]Total number of days in a delirious state
- ICU stay [ Time Frame: Through study completion, an average of 30 days ]The duration of days admitted in the ICU and in the hospital
- Total dose of analgesics [ Time Frame: Through study completion, an average of 30 days ]Total dose of analgesics used in the ICU
- Total dose of vasopressors [ Time Frame: Through study completion, an average of 30 days ]Total dose of vasopressors used in the ICU
- Pace maker necessitation [ Time Frame: Through study completion, an average of 30 days ]Number of patients needing external pacing
- costs [ Time Frame: Through study completion, an average of 30 days ]Estimated total cost of hospital stay per day
- Hospital stay [ Time Frame: Through study completion, an average of 30 days ]The duration of days admitted in the hospital
- Total dose sedatives [ Time Frame: Through study completion, an average of 30 days ]Total dose of sedatives used in the ICU
- Total dose of inotropic agents [ Time Frame: Through study completion, an average of 30 days ]Total dose of inotropic agents used in the ICU
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03388541
|Contact: Mona MOMENI, MD,PhDemail@example.com|
|Cliniques Universitaires Saint Luc||Recruiting|
|Brussels, Belgium, 1200|
|Principal Investigator: MONA MOMENI, M.D.; PhD|
|Principal Investigator:||Mona Momeni, MD,PhD||Cliniques universitaires Saint-Luc|